August 18, 2020 -- Agilent Technologies said that it's expanding its Frederick, CO-based production facility to more than double its current capacity for developing the short DNA and RNA molecules used to create nucleic acid-based therapeutics.
Adding the higher-volume manufacturing line will help Agilent meet expected growth in demand from pharmaceutical and biotech companies for these molecules, called oligos, according to the company. Oligos have the potential to be used to develop treatments for cancer, COVID-19, cardiovascular disease, rare and infectious diseases, and other conditions, Agilent said.
The company expects to begin shipping molecules manufactured on the new line by the end of 2022.
Copyright © 2020 scienceboard.net